Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06399900 · ClinicalTrials.gov registry record · NA
ENhancing Exercise with LIGHT to Improve Functioning in PAD
A NA study of Aging and Peripheral Artery Disease, sponsored by Northwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06399900: Recruiting NA study of Aging and Peripheral Artery Disease, sponsored by Northwestern University.
NCT06399900 is a NA study of Aging and Peripheral Artery Disease that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 32 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06399900, a NA study of Aging and Peripheral Artery Disease, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).
Primary Outcome
Change in six-minute walk distance
Conditions Studied
Interventions
- DEVICE Far red light therapy
- DEVICE Sham light therapy
- BEHAVIORAL Home-based walking exercise
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2027-01-31 |
| Phase | NA |
What NCT06399900 shows while recruiting
NCT06399900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Far red light therapy is the first listed.
NCT06399900 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06399900 about?
NCT06399900 is a clinical study titled "ENhancing Exercise with LIGHT to Improve Functioning in PAD". The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity periphera...
What is the current status of trial NCT06399900?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2024-08-12. Estimated completion is 2027-01-31.
What conditions does trial NCT06399900 study?
This clinical trial studies the following conditions: Aging, Peripheral Artery Disease, Peripheral Vascular Disease, Walking, Difficulty.
What interventions are being tested in trial NCT06399900?
The interventions under investigation include: Far red light therapy (DEVICE), Sham light therapy (DEVICE), Home-based walking exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT06399900?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06399900 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06399900's enrollment target sits among peer trials
32 188th of 262 higher than 72 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Using Nicotine to Reverse Age-related Auditory Processing Deficits
RECRUITING · NA
-
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
-
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
RECRUITING · NA
-
The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI